A combination of the main constituents of Fufang Xueshuantong Capsules shows protective effects against streptozotocin-induced retinal lesions in rats

Journal of Ethnopharmacology

Volumn 182, Issue , 2016, Pages 50-56

  Jian, Weijie ^a   Yu, Suyun ^a   Tang, Minke ^a   Duan, Huihui ^a   Huang, Jianmei ^a  

^a BEIJING UNIVERSITY OF CHINESE MEDICINE   (China)

Author keywords

Diabetic retinopathy; Endothelin 1; Fufang Xueshuantong Capsule; Intercellular adhesion molecule 1; Occludin; Pigment epithelium derived factor

Indexed keywords

ALDEHYDE REDUCTASE; ASTRAGALOSIDE A; CRYPTOTANSHINONE; ENDOTHELIN 1; FUFANG XUESHUANTONG; GLUCOSE; HARPAGOSIDE; HERBACEOUS AGENT; INTERCELLULAR ADHESION MOLECULE 1; NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE; OCCLUDIN; PANAX NOTOGINSENG EXTRACT; PIGMENT EPITHELIUM DERIVED FACTOR; PROTECTIVE AGENT; SAPONIN; STREPTOZOCIN; TANSHINONE I; TRYPSIN; UNCLASSIFIED DRUG; VASCULOTROPIN; ANTIDIABETIC AGENT; EYE PROTEIN; GLUCOSE BLOOD LEVEL; MICROCAPSULE; NERVE GROWTH FACTOR; OCLN PROTEIN, RAT; PIGMENT EPITHELIUM-DERIVED FACTOR; SERINE PROTEINASE INHIBITOR; VASCULAR ENDOTHELIAL GROWTH FACTOR A, RAT; VASCULOTROPIN A;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLOOD RHEOLOGY; BLOOD VISCOSITY; BODY WEIGHT; CELL LOSS; CONTROLLED STUDY; DRUG IDENTIFICATION; ERYTHROCYTE AGGREGATION; EYE PROTECTION; GLUCOSE BLOOD LEVEL; MALE; MICROCAPSULE; NONHUMAN; PERICYTE; PLASMA VISCOSITY; PROTEIN EXPRESSION; RAT; RETINA DISEASE; ULTRAVIOLET SPECTROPHOTOMETRY; WEIGHT GAIN; ANALYSIS; ANIMAL; BLOOD; DIABETES MELLITUS, EXPERIMENTAL; DIABETIC RETINOPATHY; DRUG EFFECTS; METABOLISM; PHYTOTHERAPY; RETINA; SPRAGUE DAWLEY RAT;

ANIMALS; BLOOD GLUCOSE; CAPSULES; DIABETES MELLITUS, EXPERIMENTAL; DIABETIC RETINOPATHY; DRUGS, CHINESE HERBAL; ENDOTHELIN-1; EYE PROTEINS; HYPOGLYCEMIC AGENTS; INTERCELLULAR ADHESION MOLECULE-1; MALE; NERVE GROWTH FACTORS; OCCLUDIN; PHYTOTHERAPY; RATS; RATS, SPRAGUE-DAWLEY; RETINA; SAPONINS; SERPINS; STREPTOZOCIN; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84977270271     PISSN: 03788741     EISSN: 18727573     Source Type: Journal    
DOI: 10.1016/j.jep.2015.11.021     Document Type: Article

References (31)

1. Abu El-Asrar, A.M., Midena, E., Al-Shabrawey, M., Mohammad, G., New developments in the pathophysiology and management of diabetic retinopathy. J. Diabetes Res., 2013, 2013, 424258.
2. Akileshwari, C., Muthenna, P., Nastasijevic, B., Joksic, G., Petrash, J.M., Reddy, G.B., Inhibition of aldose reductase by Gentiana lutea extracts. Exp. Diabetes Res., 2012, 2012, 147965.
3. Bandello, F., Lattanzio, R., Zucchiatti, I., Del Turco, C., Pathophysiology and treatment of diabetic retinopathy. Acta Diabetol. 50 (2013), 1–20.
4. Bucolo, C., Leggio, G.M., Drago, F., Salomone, S., Eriodictyol prevents early retinal and plasma abnormalities in streptozotocin-induced diabetic rats. Biochem. Pharmacol. 84 (2012), 88–92.
5. Bucolo, C., Ward, K.W., Mazzon, E., Cuzzocrea, S., Drago, F., Protective effects of a coumarin derivative in diabetic rats. Investig. Ophthalmol. Vis. Sci. 50 (2009), 3846–3852.
6. Cheng, Y.X., Clinical effect observation of compound xueshuantong capsule in the treatment of diabetic retinopathy. Guide China Med. 11 (2013), 215–216.
7. De Juan, J.A., Moya, F.J., Ripodas, A., Bernal, R., Fernandez-Cruz, A., Fernandez-Durango, R., Changes in the density and localisation of endothelin receptors in the early stages of rat diabetic retinopathy and the effect of insulin treatment. Diabetologia 43 (2000), 773–785.
8. Ding, Y., Yuan, S., Liu, X., Mao, P., Zhao, C., Huang, Q., Zhang, R., Fang, Y., Song, Q., Yuan, D., Xie, P., Liu, Y., Liu, Q., Protective effects of astragaloside IV on db/db mice with diabetic retinopathy. Plos One, 9, 2014, e112207.
9. Duan, H., Huang, J., Li, W., Tang, M., Protective effects of Fufang Xueshuantong on diabetic retinopathy in rats. Evid. Based Complement. Altern. Med., 2013, 2013, 408268.
10. Hattori, T., Matsubara, A., Taniguchi, K., Ogura, Y., Aldose reductase inhibitor fidarestat attenuates leukocyte-endothelial interactions in experimental diabetic rat retina in vivo. Curr. Eye Res. 35 (2010), 146–154.
11. Hotta, N., Kawamori, R., Fukuda, M., Shigeta, Y., Long-term clinical effects of epalrestat, an aldose reductase inhibitor, on progression of diabetic neuropathy and other microvascular complications: multivariate epidemiological analysis based on patient background factors and severity of diabetic neuropathy. Diabet. Med. 29 (2012), 1529–1533.
12. Ibrahim, A.S., El-Remessy, A.B., Matragoon, S., Zhang, W., Patel, Y., Khan, S., Al-Gayyar, M.M., El-Shishtawy, M.M., Liou, G.I., Retinal microglial activation and inflammation induced by amadori-glycated albumin in a rat model of diabetes. Diabetes 60 (2011), 1122–1133.
13. Jin, Y.C., Kim, C.W., Kim, Y.M., Nizamutdinova, I.T., Ha, Y.M., Kim, H.J., Seo, H.G., Son, K.H., Jeon, S.J., Kang, S.S., Kim, Y.S., Kam, S.C., Lee, J.H., Chang, K.C., Cryptotanshinone, a lipophilic compound of Salvia miltiorrriza root, inhibits TNF-alpha-induced expression of adhesion molecules in HUVEC and attenuates rat myocardial ischemia/reperfusion injury in vivo. Eur. J. Pharmacol. 614 (2009), 91–97.
14. Kim, S.R., Lee, K.Y., Koo, K.A., Sung, S.H., Lee, N.G., Kim, J., Kim, Y.C., Four new neuroprotective iridoid glycosides from Scrophularia buergeriana roots. J. Nat. Prod. 65 (2002), 1696–1699.
15. Matsuda, S., Tam, T., Singh, R.P., Kaiser, P.K., Petkovsek, D., Carneiro, G., Zanella, M.T., Ehlers, J.P., The impact of metabolic parameters on clinical response to VEGF inhibitors for diabetic macular edema. J. Diabetes Complicat. 28 (2014), 166–170.
16. Miyamoto, K., Khosrof, S., Bursell, S.E., Moromizato, Y., Aiello, L.P., Ogura, Y., Adamis, A.P., Vascular endothelial growth factor (VEGF)-induced retinal vascular permeability is mediated by intercellular adhesion molecule-1 (ICAM-1). Am. J. Pathol. 156 (2000), 1733–1739.
17. Nentwich, M.M., Ulbig, M.W., Diabetic retinopathy-ocular complications of diabetes mellitus. World J. Diabetes 6 (2015), 489–499.
18. Ogata, N., Wada, M., Otsuji, T., Jo, N., Tombran-Tink, J., Matsumura, M., Expression of pigment epithelium-derived factor in normal adult rat eye and experimental choroidal neovascularization. Investig. Ophthalmol. Vis. Sci. 43 (2002), 1168–1175.
19. Ohashi, R., Yan, S., Mu, H., Chai, H., Yao, Q., Lin, P.H., Chen, C., Effects of homocysteine and ginsenoside Rb1 on endothelial proliferation and superoxide anion production. J. Surg. Res. 133 (2006), 89–94.
20. Onitsuka, M., Fujiu, M., Shinma, N., Maruyama, H.B., New platelet aggregation inhibitors from Tan-Shen; radix of Salvia miltiorrhiza Bunge. Chem. Pharm. Bull. 31 (1983), 1670–1675.
21. Park, K., Chen, Y., Hu, Y., Mayo, A.S., Kompella, U.B., Longeras, R., Ma, J.X., Nanoparticle-mediated expression of an angiogenic inhibitor ameliorates ischemia-induced retinal neovascularization and diabetes-induced retinal vascular leakage. Diabetes 58 (2009), 1902–1913.
22. Safi, S.Z., Qvist, R., Kumar, S., Batumalaie, K., Ismail, I.S., Molecular mechanisms of diabetic retinopathy, general preventive strategies, and novel therapeutic targets. Biomed. Res. Int., 2014, 2014, 801269.
23. Sheng, S., Wang, Y., Long, C., Su, W., Rong, X., Chinese medicinal formula Fufang Xueshuantong capsule could inhibit the activity of angiotensin converting enzyme. Biotechnol. Biotechnol. Equip. 28 (2014), 322–326.
24. Stitt, A.W., Bhaduri, T., McMullen, C.B., Gardiner, T.A., Archer, D.B., Advanced glycation end products induce blood-retinal barrier dysfunction in normoglycemic rats. Mol. Cell. Biol. Res. Commun. 3 (2000), 380–388.
25. Sun, K., Wang, C.S., Guo, J., Horie, Y., Fang, S.P., Wang, F., Liu, Y.Y., Liu, L.Y., Yang, J.Y., Fan, J.Y., Han, J.Y., Protective effects of ginsenoside Rb1, ginsenoside Rg1, and notoginsenoside R1 on lipopolysaccharide-induced microcirculatory disturbance in rat mesentery. Life Sci. 81 (2007), 509–518.
26. Yamagishi, S., Matsui, T., Advanced glycation end products (AGEs), oxidative stress and diabetic retinopathy. Curr. Pharm. Biotechnol. 12 (2011), 362–368.
27. Yamagishi, S., Matsui, T., Nakamura, K., Inoue, H., Takeuchi, M., Ueda, S., Okuda, S., Imaizumi, T., Olmesartan blocks inflammatory reactions in endothelial cells evoked by advanced glycation end products by suppressing generation of reactive oxygen species. Ophthalmic Res. 40 (2008), 10–15.
28. Yamagishi, S., Matsui, T., Nakamura, K., Ueda, S., Noda, Y., Imaizumi, T., Pigment epithelium-derived factor (PEDF): its potential therapeutic implication in diabetic vascular complications. Curr. Drug Targets 9 (2008), 1025–1029.
29. Yang, Y., Hayden, M.R., Sowers, S., Bagree, S.V., Sowers, J.R., Retinal redox stress and remodeling in cardiometabolic syndrome and diabetes. Oxid. Med. Cell. Longev. 3 (2010), 392–403.
30. Yu, S., Yang, L., Wang, Y., Fu, Q., Huang, J., Xie, C., Chen, X., Application of quantitative analysis of multi-components by single-marker in detection of eight components of Fufang Xueshuantong Capsule. J. Int. Pharm. Res. 42 (2014), 231–237.
31. Zhou, Z., Wang, S.Q., Liu, Y., Miao, A.D., Cryptotanshinone inhibits endothelin-1 expression and stimulates nitric oxide production in human vascular endothelial cells. Biochim. Biophys. Acta 1760 (2006), 1–9.